Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
Nuevolution A/S announced that it has entered into a drug discovery collaboration with Merck & Co. Inc. Nuevolution will apply its proprietary Chemetics® drug discovery technology to identify novel small molecule leads against several drug targets of interest to Merck. T
Nuevolution will screen multiple multi-million member diverse fragment based screening libraries for hit identification. Through the design, synthesis and screening of target focused Chemetics® follow-up libraries, the parties will also work together to perform hit-to-lead optimization.
Under the terms of the agreement, Merck will provide Nuevolution with an upfront payment, research funding, and milestone payments as candidate molecules progress through preclinical and clinical development and onto the market. In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products. Further financial details were not disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
